February 2005 Vol. 1 No. 2 CD0493
As with most investments, the sooner you begin -
the bigger the long-term rewards.
This especially holds true for calves.
The first few weeks in the life of a calf are the most critical
in terms of health protection. The newborn calf enters
a world saturated with pathogens and
little protection against disease organisms.
Timing of treatment is a key factor when using
medicated feed for your calves. The more you know,
the more informed decision you’ll be able to make
to protect your investment.
Treating Early Can Make A Sizable Difference
Even before calves show signs of illness, sub-clinical infections can silently erode
gains. Treating calves early, before they become clinically ill, provides antimicrobials
to those calves not easily recognizable as sick.
- Research shows that Aureo S 700® helps calves fight
off important respiratory bacteria.
- Antimicrobials don’t kill all the targeted bacteria. The calf must eliminate
infection on its own, with the aid of a healthy immune system.
- Thus, any action by antimicrobials that is deleterious to bacteria
helps the calf overcome infection.
- Recent findings show that Aureo S 700 effectively reduces the growth
of both Haemophilus somnus and Mannheimia haemolytica,1 helping the calf overcome infection with these two important respiratory bacteria.
- Aureo S 700 is even more effective in healthy-appearing calves - so why wait?
- Research suggests that pretreatment - prior to fever - is more likely
to be effective in the treatment or prevention of BRD.1
- This supports the philosophy that Aureo S 700 should be used early
in disease onset when calves are not critically ill.1
- Aureo S 700 is proven to reduce lung lesions caused by H. somnus by 88%.2
- Only Aureo S 700 contains both Aureomycin® and sulfamethazine in each granule,
along with the Aureomycin guarantee.
- Aureo S 700 granulation ensures uniform distribution so calves get a full effective dose.
- Granular formulation flows freely with minimum dust and fines.
- Feedmill studies show that carry-over risk is reduced by using granular products.3
References
- Sub-MIC effects of Aureomycin®, Aureo S 700®,
and temperature on growth kinetics and outer
membrane protein expression in Mannheimia
haemolytica and Haemophilus somnus. 2004.
Technical Bulletin No. CD 0467, pp.1-8.
- Effects of Aureo S 700® and Aureomycin®
in reducing lung lesions in Haemophilus
somnus-challenged calves. 2002. Technical
Bulletin No. CD 0329, pp. 1-2.
- Data on file, Alpharma Animal Health.
Aureomycin and Aureo S 700 are registered trademarks of Alpharma.
© 2005 Alpharma Inc. All rights reserved.
Alpharma Inc.
One Executive Drive
Fort Lee, NJ 07024, USA
Tel: (800) 643-5791
www.alpharma.com